Lyell Immunopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell LYEL and other ETFs, options, and stocks.

About LYEL

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. 

CEO
Lynn Seely
CEOLynn Seely
Employees
161
Employees161
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2018
Founded2018
Employees
161
Employees161

LYEL Key Statistics

Market cap
296.81M
Market cap296.81M
Price-Earnings ratio
-1.00
Price-Earnings ratio-1.00
Dividend yield
Dividend yield
Average volume
126.85K
Average volume126.85K
High today
$13.03
High today$13.03
Low today
$12.17
Low today$12.17
Open price
$12.50
Open price$12.50
Volume
99.18K
Volume99.18K
52 Week high
$45.00
52 Week high$45.00
52 Week low
$8.46
52 Week low$8.46

Stock Snapshot

As of today, Lyell Immunopharma(LYEL) shares are valued at $12.70. The company's market cap stands at 296.81M, with a P/E ratio of -1.00.

On 2026-06-10, Lyell Immunopharma(LYEL) stock traded between a low of $12.17 and a high of $13.03. Shares are currently priced at $12.70, which is +4.4% above the low and -2.5% below the high.

Lyell Immunopharma(LYEL) shares are trading with a volume of 99.18K, against a daily average of 126.85K.

In the last year, Lyell Immunopharma(LYEL) shares hit a 52-week high of $45.00 and a 52-week low of $8.46.

In the last year, Lyell Immunopharma(LYEL) shares hit a 52-week high of $45.00 and a 52-week low of $8.46.

LYEL News

Simply Wall St 22h
Here's Why We're Watching Lyell Immunopharma's Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon....

Here's Why We're Watching Lyell Immunopharma's Cash Burn Situation
Benzinga 2d
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update - Benzinga

...

Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update - Benzinga
TipRanks 2d
Lyell Immunopharma provides update on safety profile of LYL273

Lyell Immunopharma (LYEL) provided an update on the safety profile of LYL273 in its ongoing U.S. Phase 1 clinical trial in patients with relapsed or refractory...

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
0%
Sell
16.7%

More LYEL News

Nasdaq 6d
Lyell Immunopharma Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

A downtrend has been apparent in Lyell Immunopharma (LYEL) lately with too much selling pressure. The stock has declined 39.7% over the past four weeks. However...

Lyell Immunopharma Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

People also own

Based on the portfolios of people who own LYEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.